Business
Alumis Stockholders Approve Merger with ACELYRIN
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with ACELYRIN, INC. (Nasdaq: SLRN) at its Special Meeting of Stockholders. Mart
About this update from Alumis Inc.
[{"type":"image","alt":"Alumis Inc.","displaySize":"","headline":null,"caption":"Alumis Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":39,"url":"https://media.zenfs.com/en/globenewswire.com/cd047612371c6f86746cf01631a6f911"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/D1V_aGoKejvy_01T3BfhbQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTU1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/cd047612371c6f86746cf01631a6f911","width":150,"height":39}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with ACELYRIN, INC. (Nasdaq: SLRN) at its Special Meeting of Stockholders.","length":495,"tagName":"p"},{"type":"text","content":"Martin Babler, President, Chief Executive Officer and Chairman of Alumis, said, “We thank our stockholders for their support for the merger and with this milestone now complete, we are moving expeditiously toward closing. We are looking forward to maximizing the value of our portfolio and advancing breakthroughs in immune-mediated diseases with the support of a significantly strengthened financial foundation.”","length":413,"tagName":"p"},{"type":"text","content":"The final voting results of the Alumis Special Meeting will be reported in a Form 8-K filed by Alumis with the U.S. Securities and Exchange Commission.","length":151,"tagName":"p"},{"type":"text","content":"The merger is expected to close in the second quarter of 2025, subject to satisfaction of certain customary closing conditions.","length":127,"tagName":"p"},{"type":"text","content":"About Alumis","length":12,"tagName":"p"},{"type":"text","content":"Alumis is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases. Leveraging its proprietary precision data analytics platform, Alumis is building a pipeline of molecules with the potential to address a broad range of immune-mediate...